- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02147132
Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients
December 4, 2018 updated by: Theresa Winhusen, University of Cincinnati
A Pilot Randomized, Placebo-Controlled, Crossover Study of the Effect of the Nicotine Nasal Spray and Varenicline on Cigarette Smoking Following Methadone Dosing in Methadone-Maintained Patients
The objective is to provide a preliminary test of the ability of two pharmacological treatments, the nicotine nasal spray and varenicline, relative to placebos, to reduce smoking during the 4 hours following methadone dosing.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Detailed Description
Smoking prevalence is over 83% in methadone-maintained patients.
These patients experience significant difficulty quitting, and there is evidence that a majority of methadone-maintained patients smoke most of their cigarettes in the 4 hours following methadone dosing.
The objective is to provide a preliminary test of the ability of two pharmacological treatments, the nicotine nasal spray and varenicline, relative to placebos, to reduce smoking during the 4 hours following methadone dosing.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- UC Physicians Company, LLC Opioid Treatment Program
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- be male or female, 18 years of age or older
- be able to understand the study, and having understood, provide written informed consent in English
- have been enrolled in the University of Cincinnati Physicians Company-Opioid Treatment Program (UCPC-OTP) program for at least 30 days and be stable on the current methadone dose for at least 1 week
- have smoked cigarettes for at least 3 months, have a measured exhaled carbon monoxide (CO) level > 8 parts per million (ppm), and not planning to seek smoking-cessation treatment within the next 3 months
- have a willingness to comply with all study procedures, including trying to stop smoking during designated weeks, and to comply with medication instructions
- based on a week of Quitbit cigarette lighter assessments, with at least 5 days of usable data, smoke ≥ 10 cigarettes/day and smoke at least 30% of daily cigarettes within the 4-hour post-methadone-dosing period
- if female and of child bearing potential, agree to use one of the following methods of birth control: oral contraceptives, contraceptive patch, barrier (diaphragm or condom), intrauterine contraceptive system, levonorgestrel implant, medroxyprogesterone acetate contraceptive injection,complete abstinence from sexual intercourse, hormonal vaginal contraceptive ring.
Exclusion Criteria:
- have a current or past diagnosis of any psychotic disorder, or bipolar I or II disorder
- have a psychiatric condition that, in the judgment of the study physician would make study participation unsafe or which would make treatment compliance difficult
- be a significant suicidal/homicidal risk
have a medical condition that, in the judgment of the study physician, would make study participation unsafe or which would make treatment compliance difficult. Such conditions include, but are not limited to:
- liver function tests greater than 3 times upper limit of normal
- serum creatinine greater than 2 mg/dL
- have had clinically significant cardiovascular or cerebrovascular disease within the past 6 months or have clinically significant ECG abnormalities
- have taken an investigational drug within 30 days before consent
- be taking concomitant medications that are contraindicated for use with the NNS or varenicline
- be taking any concomitant medications that could increase the likelihood of smoking cessation (such as wellbutrin or nortriptyline)
- have a known or suspected hypersensitivity to varenicline or the nicotine nasal spray (NNS)
- use/have used smoking-cessation counseling programs with individual counseling or smoking-cessation medication treatments currently, or within 30 days before consent
- have used electronic cigarettes or tobacco products, other than cigarettes, in the week before consent
- be pregnant or breastfeeding
- be anyone who, in the judgment of the investigator, would not be expected to complete the study protocol (e.g., due to relocation from the clinic area, probable incarceration, etc.)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Order 1
Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
|
7 days.
1 mg/dose, up to 40x/day.
14 days.
Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
7 days.
1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day.
This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
14 days.
Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
This will appear identical to the drug Varenicline, but will be a placebo.
|
EXPERIMENTAL: Order 2
Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
|
7 days.
1 mg/dose, up to 40x/day.
14 days.
Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
7 days.
1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day.
This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
14 days.
Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
This will appear identical to the drug Varenicline, but will be a placebo.
|
EXPERIMENTAL: Order 3
Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7).
|
7 days.
1 mg/dose, up to 40x/day.
14 days.
Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
7 days.
1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day.
This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
14 days.
Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
This will appear identical to the drug Varenicline, but will be a placebo.
|
EXPERIMENTAL: Order 4
Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7).
|
7 days.
1 mg/dose, up to 40x/day.
14 days.
Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
7 days.
1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day.
This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
14 days.
Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
This will appear identical to the drug Varenicline, but will be a placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Daily Cigarettes Smoked in the 4 Hours After Receiving Methadone Dose
Time Frame: 7 weeks
|
Subjects will be given a special electronic cigarette lighter called Quitbit.The electronic lighter will record a timestamp for each time the lighter is used to light a cigarette.
Data will be collected from the lighter at each study visit.
This will measure how many cigarettes are smoked and when.
|
7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cigarettes Per Day
Time Frame: 7 weeks
|
The Quitbit lighter will measure how many cigarettes are smoked per day.
In addition to the Quitbit lighter measurement, the Timeline Follow Back (TLFB) form will be filled out for each subject to measure use, as well.
|
7 weeks
|
Number of Participants With Carbon Monoxide Levels Less Than or Equal to 8 Parts-per-million
Time Frame: up to 8 weeks
|
Carbon monoxide (CO) in each participant's breath will be tested.
A CO level less than or equal to 8 parts-per-million will be used to verify reports of no smoking.
|
up to 8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2016
Primary Completion (ACTUAL)
August 25, 2017
Study Completion (ACTUAL)
August 25, 2017
Study Registration Dates
First Submitted
May 19, 2014
First Submitted That Met QC Criteria
May 21, 2014
First Posted (ESTIMATE)
May 26, 2014
Study Record Updates
Last Update Posted (ACTUAL)
December 5, 2018
Last Update Submitted That Met QC Criteria
December 4, 2018
Last Verified
December 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-7275
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cigarette Smoking
-
Maastricht University Medical CenterCompletedCigarette Smoking | Cigarette Smoking Toxicity | Smoking BehaviorNetherlands
-
Duke UniversityGeorgetown University; University of MichiganWithdrawnSmoking | Cigarette Smoking | E-cigarette Use
-
Assistance Publique - Hôpitaux de ParisUnknownSmoking Cessation | Smoking, Cigarette | Electronic CigaretteFrance
-
Yale UniversityNational Cancer Institute (NCI)RecruitingSmoking Cessation | Cigarette Smoking | E-Cigarette UseUnited States
-
Medical University of South CarolinaAmerican Cancer Society, Inc.RecruitingSmoking Cessation | Electronic Cigarette Use | Cigarette SmokingUnited States
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); New York University; Stanford UniversityRecruitingSmoking | Smoking, Tobacco | Smoking, CigaretteUnited States
-
University of St AndrewsNational Health Service, United KingdomUnknownSmoking | Cigarette Smoking | Smoking, Tobacco
-
BIDI VaporCompletedCigarette Smoking | E-cigarette UsePoland
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
Clinical Trials on Nicotine Nasal Spray
-
University of LausannePharmaciaCompletedSmoking CessationSwitzerland
-
El Instituto Nacional de Neurologia y Neurocirugia...Howard UniversityCompleted
-
VistaGen Therapeutics, Inc.TerminatedSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.RecruitingSocial Anxiety DisorderUnited States
-
VistaGen Therapeutics, Inc.CompletedSocial Anxiety DisorderUnited States
-
University of ChicagoMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.Withdrawn
-
Viiral Nordic ABCompleted
-
Imperial College LondonGlaxoSmithKlineCompleted
-
Oyster Point Pharma, Inc.CompletedDry Eye DiseaseUnited States
-
Toby WeingartenCompletedPain, PostoperativeUnited States